		1	_
١	,	1	n
٠,	,	- 1	 u

Follow-Up: Breast

= HCM	B	
	PA	
Contract of the contract of th		O Y
1000	200	
- March	20/0	

Tissue Source Site (TSS) Name:	HCMI Identifier (ID3):
Completed By:	Completion Date (MM/DD/YYYY):

Form Notes: A Follow-Up Form should be completed for each HCMI case upon notice of model establishment and molecular characterization success from Leidos. All information provided on this form should include activity from the "Date of Last Contact" provided on the HCMI Enrollment Form to the most recent date of contact with the patient or the patient's medical record.

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
1	ID2		2003301	Provide the patient's ID2 (this ID will only be used
				by IMS for internal quality control).
2	ID3		5845012	Provide the HCMI-specific anonymized ID (ID3).
3	Index date		6154722	Select the reference date used to calculate time
		- Interest weak allowed a discounts		intervals (e.g. days to treatment). Date of initial
		☐ Initial pathologic diagnosis☐ Sample procurement		pathologic diagnosis is the HCMI standard and
		☐ First patient visit		should be used unless it is unavailable. If an
		Trist patient visit		alternative index date is used, indicate it here and use it for all interval calculations.
Follow-Up F	Patient Status		L	
4	Number of days		3008273	Provide the number of days from the index date
	from index date to			to the last date of follow-up with the patient or
	date of last			last contact with the medical record.
5	follow-up Vital status		5	Indicate whether the nations is alive dead or lest
5	Vildi Status	☐ Alive	3	Indicate whether the patient is alive, dead, or lost to follow-up at the date of last contact.
		□ Dead		Note: If the patient is deceased, continue to
		☐ Lost to follow-up		Question 6, otherwise skip to Question 8.
6	Number of days		3165475	Provide the number of days from the index date
	from index date to			to the date of death.
	date of death			
7	Cause of death	Related to this cancer	2554674	Indicate the patient's cause of death.
		☐ Non-cancer related		
		Related to another cancer		
		☐ Other (specify) ☐ Unknown		
	Other cause of	Unknown	4783275	If the cause of death is not included in the
7 a	death		4703273	provided list, specify the cause of death.
8	Disease status at	☐ No evidence of disease	2188290	Provide the last known state of the patient's
	follow-up	☐ Stable disease		tumor up to the point of current follow-up data
		☐ Progressive disease		submission.
		□ Unknown		
	Information	T	2978013	I la disease wheels are consequently as a series and the broad
9	Was surgery performed as part	│	29/8013	Indicate whether surgery was performed to treat the primary tumor.
	of the primary	□ No		Note: If the patient did not receive surgical
	disease treatment	☐ Unknown		treatment, skip to Question 11.
	plan?			a commonly simple Question ==:
10	Number of days		3008335	Provide the number of days from the index date
	from index date to			to the date of surgical treatment.
	date of surgical			
	treatment			
11	Was systemic		3397567	Indicate whether the patient received systemic
	adjuvant therapy	☐ Yes		adjuvant pharmaceutical therapy.
	administered?	□ No □ Unknown		Note: If the patient did have systemic adjuvant
		L Olikilowii		therapy, the Pharmaceutical Supplemental Form should be completed.
12	Was adjuvant		2005312	Indicate whether the patient had adjuvant
	radiation therapy	☐ Yes	2003312	radiation therapy.
	administered?	□ No		Note: If the patient had adjuvant radiation
		☐ Unknown		therapy, the Radiation Supplemental Form
				should be completed.

11	4		\sim
V	Ш	١.	0

V1.0		HCMI	
	Follow-Up: Breast		
Tissue Source Site (TSS) Name:	HCMI Identifier (ID3):	44	1
Completed By:	Completion Date (MM/DD/YYYY):		

Pharmaceutical Supplemental Form

Form Notes: A Pharmaceutical Supplemental Form should be completed for each HCMI case for which the patient received adjuvant pharmaceutical therapy. All information provided on this form should include activity from the "Date of Last Contact" provided on the HCMI Enrollment Form to the most recent date of contact with the patient or the patient's medical record.

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
1	Was cytotoxic chemotherapy administered?	☐ Yes ☐ No ☐ Unknown	5628399	Indicate whether the patient received cytotoxic chemotherapy. Note: If cytotoxic chemotherapy was administered, proceed to the "Cytotoxic Chemotherapy" section, Questions 5-8.
2	Was Hormone therapy administered?	☐ Yes ☐ No ☐ Unknown	6385020	Indicate whether the patient received hormone therapy. Note: If hormone therapy was administered, proceed to the "Hormone Therapy" section, Questions 9-12.
3	Was immunotherapy (cellular and immune checkpoint) administered?	☐ Yes ☐ No ☐ Unknown	3057655	Indicate whether the patient received immunotherapy. Note: If immunotherapy was administered, proceed to the "Immunotherapy" section, Questions 13-16.
4	Was targeted therapy (small molecule inhibitors and targeted antibodies) administered?	☐ Yes ☐ No ☐ Unknown	2785850	Indicate whether the patient received targeted therapy. Note: If targeted therapy was administered, proceed to the "Targeted Therapy" section, Questions 17-20.
Cytotoxic Cl	hemotherapy		1	
5	Chemotherapeutic administered	☐ 5-fluorouracil ☐ Albumin-bound paclitaxel ☐ Capecitabine ☐ Carboplatin ☐ Cisplatin ☐ Cyclophosphamide ☐ Docetaxel ☐ Epirubicin ☐ Eribulin ☐ Gemcitabine ☐ Ixabepilone ☐ Lapatinib ☐ Liposomal doxorubicin ☐ Methotrexate ☐ Mitoxantrone ☐ Neratinib ☐ Paclitaxel ☐ T-DM1 ☐ Trastuzumab ☐ Vinorelbine ☐ Other (specify)	2853873	Select the chemotherapeutic used for therapy. Note: Questions 5-8 are repeatable as needed to capture each individual chemotherapeutic administered. If the chemotherapeutic is not included in the provided list, proceed to Question 5a, otherwise, skip to Question 6.
5a	Other chemotherapeutic		2514640	If the adjuvant therapy is not included in the provided list, specify adjuvant therapy.
6	Days from index date to start of pharmaceutical treatment		5102411	Provided list, specify adjuvant therapy. Provide the number of days from the index date to the date of initiation of treatment with adjuvant pharmaceutical therapy.

		1	_
١	,	1	n
٠,	,	- 1	 u

Follow-Up: Breast

= HCM	B	
	200	
Contract of		
1	44	8

Tissue Source Site (TSS) Name:	HCMI Identifier (ID3):		
Completed By:	Completion Date (MM/DD/YYYY):		

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
7	Days from index date to last known date of		65167	Provide the number of days from the index date to the last known date of pharmaceutical treatment.
	pharmaceutical treatment			
8	Is the patient still receiving treatment?	☐ Yes ☐ No ☐ Unknown	6379568	Indicate whether the patient is still undergoing treatment.
Hormone T		- CHRISTI		
9	Hormone therapy administered	☐ Anastrazole ☐ CDK4/6 inhibitor ☐ Exemestane ☐ Fulvestrant ☐ Letrozole ☐ LHRH agonist ☐ Tamoxifen ☐ Toremifene ☐ Other (specify)	2582817	Select the hormone therapy administered. Note: Questions 9-12 are repeatable as needed to capture each individual hormone therapy administered. If the hormone therapy is not included in the provided list, proceed to Question 9a, otherwise, skip to Question 10.
9a	Other hormone therapy		2405358	If the hormone therapy is not included in the provided list, specify the therapy.
10	Days from index date to start of hormone therapy treatment		5102411	Provide the number of days from the index date to the date of the initiation of treatment with hormone therapy.
11	Days from index date to last known date of hormone therapy treatment		65167	Provide the number of days from the index date to the last known date of hormone therapy treatment.
12	Is the patient still receiving treatment?	☐ Yes ☐ No ☐ Unknown	6379568	Indicate whether the patient is still undergoing treatment.
Immunothe			I	
13	Immunotherapy administered		2185614	Select the immunotherapy administered. Note: Questions 13-16 are repeatable as needed to capture each individual immunotherapy administered.
14	Days from index date to start of immunotherapy treatment		5102411	Provide the number of days from the index date to the date of the initiation of treatment with immunotherapy.
15	Days from index date to last known date of immunotherapy treatment		65167	Provide the number of days from the index date to the last known date of immunotherapy treatment.
16	Is the patient still receiving treatment?	☐ Yes ☐ No ☐ Unknown	6379568	Indicate whether the patient is still undergoing treatment.

		1	_
١	,	1	n
٠,	,	- 1	 u

V1.0		HCMI
	Follow-Up: Breast	
Tissue Source Site (TSS) Name:	HCMI Identifier (ID3):	
Completed By:	Completion Date (MM/DD/YYYY):	

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
Targeted Th	herapy			
17	Targeted therapy administered	□ Ado-trastuzumab emtansine □ Everolimus □ Lapatinib □ Palbociclib □ Pertuzumab □ Ribociclib □ Trastuzumab □ Other (specify)	6068764	Select the hormone therapy administered. Note: Questions 17-20 are repeatable as needed to capture each individual targeted therapy administered. If the targeted therapy is not included in the provided list, proceed to Question 17a, otherwise, skip to Question 18.
17a	Other targeted therapy		4308476	If the targeted therapy is not included in the provided list, specify the therapy.
18	Days from index date to start of targeted therapy treatment		5102411	Provide the number of days from the index date to the date of initiation of treatment with targeted therapy.
19	Days from index date to last known date of targeted therapy treatment		65167	Provide the number of days from the index date to the last known date of targeted therapy treatment.
20	Is the patient still receiving treatment?	☐ Yes ☐ No ☐ Unknown	6379568	Indicate whether the patient is still undergoing treatment.

11	1	\sim
V	1	0

V1.0		HCMI	
	Follow-Up: Breast		1
Tissue Source Site (TSS) Name:	HCMI Identifier (ID3):		Tal
Completed By:	Completion Date (MM/DD/YYYY):		1

Radiation Supplemental Form

Form Notes: A Radiation Supplemental Form should be completed for each HCMI case for which the patient received adjuvant radiation therapy. All information provided on this form should include activity from the "Date of Last Contact" provided on the HCMI Enrollment Form to the most recent date of contact with the patient or the patient's medical record.

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
1	Radiation therapy administered type	□ 2D conventional □ 3D conformal □ Brachytherapy HDR □ Brachytherapy LDR □ IMRT □ Proton Beam □ Stereotactic Body RT □ Stereotactic Radiosurgery □ WBRT □ Other (specify) Unspecified	3028890	Provide the type of adjuvant radiation therapy that was administered to the patient, if not collected on the enrollment form for this patient. Note: If the radiation therapy type is not included in the provided list, proceed to Question 1a, otherwise, skip to Question 2.
1a	Other radiation therapy		3028890	If the radiation therapy type is not included in the provided list, specify the type.
2	Days from index date to start of adjuvant radiation therapy treatment		5102411	Provide the number of days from the index date to the date of treatment with adjuvant post-operative radiation therapy.
3	Days from index date to last known date of adjuvant radiation therapy treatment		65167	Provide the number of days from the index date to the last known date of radiation therapy treatment.
4	Is the patient still receiving treatment?	☐ Yes ☐ No ☐ Unknown	6379568	Indicate whether the patient is still undergoing treatment.